Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MIRM NASDAQ:MLTX NASDAQ:PHAR NASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMIRMMirum Pharmaceuticals$73.87-2.2%$57.15$36.86▼$75.74$3.79B0.94930,933 shs1.08 million shsMLTXMoonLake Immunotherapeutics$55.75+1.7%$51.68$31.42▼$58.26$3.52B1.27416,945 shs607,821 shsPHARPharming Group$14.84+1.7%$11.31$6.73▼$17.08$999.63M0.0213,690 shs8,789 shsPTGXProtagonist Therapeutics$59.05+1.6%$54.58$33.31▼$61.89$3.62B2.33657,634 shs792,267 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMIRMMirum Pharmaceuticals-2.20%+3.29%+44.50%+66.60%+68.38%MLTXMoonLake Immunotherapeutics+1.73%-0.25%+10.48%+42.73%+19.10%PHARPharming Group+1.71%+8.32%+56.19%+36.21%+98.66%PTGXProtagonist Therapeutics+1.57%+2.73%+8.11%+24.89%+38.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMIRMMirum Pharmaceuticals3.2648 of 5 stars2.60.00.04.23.51.70.6MLTXMoonLake Immunotherapeutics1.7756 of 5 stars3.41.00.00.02.22.50.0PHARPharming Group2.3567 of 5 stars3.53.00.00.03.00.00.6PTGXProtagonist Therapeutics2.1883 of 5 stars2.53.00.00.02.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMIRMMirum Pharmaceuticals 3.13Buy$74.130.35% UpsideMLTXMoonLake Immunotherapeutics 2.78Moderate Buy$74.4333.50% UpsidePHARPharming Group 3.00Buy$30.00102.16% UpsidePTGXProtagonist Therapeutics 3.00Buy$67.2013.80% UpsideCurrent Analyst Ratings BreakdownLatest PHAR, MIRM, MLTX, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/11/2025MIRMMirum PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy$89.008/8/2025MIRMMirum PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$77.00 ➝ $89.008/7/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy8/7/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform8/7/2025MIRMMirum PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetMarket Outperform ➝ Market Outperform$79.00 ➝ $81.008/7/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$77.00 ➝ $82.008/7/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$73.00 ➝ $80.008/7/2025PTGXProtagonist TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$67.00 ➝ $69.008/6/2025MLTXMoonLake ImmunotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$74.00 ➝ $82.007/28/2025MLTXMoonLake ImmunotherapeuticsRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold7/28/2025MLTXMoonLake ImmunotherapeuticsRothschild & Co RedburnSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$65.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMIRMMirum Pharmaceuticals$336.89M11.02N/AN/A$5.08 per share14.54MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$5.57 per shareN/APHARPharming Group$339.84M2.99$0.08 per share196.82$3.50 per share4.24PTGXProtagonist Therapeutics$434.43M8.46$4.59 per share12.87$10.74 per share5.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMIRMMirum Pharmaceuticals-$87.94M-$1.21N/AN/AN/A-13.65%-24.76%-8.50%11/11/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$118.94M-$2.78N/AN/AN/AN/A-40.98%-35.81%11/6/2025 (Estimated)PHARPharming Group-$11.84M-$0.13N/A494.67N/A-2.19%-3.31%-1.78%10/23/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.7084.36N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)Latest PHAR, MIRM, MLTX, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31-$0.12+$0.19-$0.12$107.91 million$127.79 million8/6/2025Q2 2025PTGXProtagonist Therapeutics-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 million8/5/2025Q2 2025MLTXMoonLake Immunotherapeutics-$0.73-$0.87-$0.14-$0.87N/AN/A7/31/2025Q2 2025PHARPharming Group-$0.10$0.06+$0.16$0.06$70.36 million$93.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMIRMMirum Pharmaceuticals1.213.132.97MLTXMoonLake Immunotherapeutics0.2116.6516.65PHARPharming Group0.382.792.07PTGXProtagonist TherapeuticsN/A16.9716.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMIRMMirum PharmaceuticalsN/AMLTXMoonLake Immunotherapeutics93.85%PHARPharming Group0.03%PTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipMIRMMirum Pharmaceuticals14.36%MLTXMoonLake Immunotherapeutics12.02%PHARPharming Group2.07%PTGXProtagonist Therapeutics4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMIRMMirum Pharmaceuticals14050.24 million43.02 millionOptionableMLTXMoonLake Immunotherapeutics264.23 million56.51 millionOptionablePHARPharming Group28068.52 million67.10 millionNot OptionablePTGXProtagonist Therapeutics12062.21 million59.16 millionOptionablePHAR, MIRM, MLTX, and PTGX HeadlinesRecent News About These CompaniesProtagonist Therapeutics (NASDAQ:PTGX) Director Sells $237,000.00 in Stock1 hour ago | insidertrades.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Buy" from Analysts5 hours ago | marketbeat.comJump Financial LLC Acquires New Position in Protagonist Therapeutics, Inc. $PTGXAugust 29 at 5:19 AM | marketbeat.comPrice T Rowe Associates Inc. MD Sells 70,646 Shares of Protagonist Therapeutics, Inc. $PTGXAugust 29 at 4:05 AM | marketbeat.comAxiom Investors LLC DE Invests $1.93 Million in Protagonist Therapeutics, Inc. $PTGXAugust 27 at 7:02 AM | marketbeat.comNuveen LLC Buys Shares of 152,771 Protagonist Therapeutics, Inc. $PTGXAugust 27 at 3:38 AM | marketbeat.comRusfertide wins Breakthrough Therapy status from FDAAugust 27 at 2:18 AM | thepharmaletter.comTProtagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025August 26, 2025 | accessnewswire.comAWellington Management Group LLP Buys 47,293 Shares of Protagonist Therapeutics, Inc. $PTGXAugust 26, 2025 | marketbeat.comState of New Jersey Common Pension Fund D Purchases Shares of 53,736 Protagonist Therapeutics, Inc. $PTGXAugust 24, 2025 | marketbeat.comProtagonist Therapeutics, Inc. $PTGX Shares Sold by American Century Companies Inc.August 24, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Sells 20,691 Shares of Protagonist Therapeutics, Inc. $PTGXAugust 23, 2025 | marketbeat.comVanguard Group Inc. Has $206.85 Million Holdings in Protagonist Therapeutics, Inc. $PTGXAugust 22, 2025 | marketbeat.comInvesco Ltd. Has $41.57 Million Position in Protagonist Therapeutics, Inc. $PTGXAugust 20, 2025 | marketbeat.comDeutsche Bank AG Has $3.18 Million Holdings in Protagonist Therapeutics, Inc. $PTGXAugust 20, 2025 | marketbeat.comE Fund Management Co. Ltd. Sells 71,950 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)August 18, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Public Sector Pension Investment BoardAugust 15, 2025 | marketbeat.comInformed Momentum Co LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)August 13, 2025 | marketbeat.comKnott David M Jr Purchases 23,632 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)August 12, 2025 | marketbeat.comDoes Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot?August 12, 2025 | finance.yahoo.comWedbush Has Positive Estimate for PTGX Q3 EarningsAugust 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli LillyBy Jordan Chussler | August 9, 20253 Biotech Catalysts Present Major OpportunityBy Nathan Reiff | August 25, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 2025PHAR, MIRM, MLTX, and PTGX Company DescriptionsMirum Pharmaceuticals NASDAQ:MIRM$73.87 -1.66 (-2.20%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$72.93 -0.94 (-1.28%) As of 08/29/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.MoonLake Immunotherapeutics NASDAQ:MLTX$55.75 +0.95 (+1.73%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$56.61 +0.86 (+1.55%) As of 08/29/2025 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Pharming Group NASDAQ:PHAR$14.84 +0.25 (+1.71%) Closing price 08/29/2025 03:58 PM EasternExtended Trading$14.57 -0.27 (-1.81%) As of 08/29/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Protagonist Therapeutics NASDAQ:PTGX$59.05 +0.91 (+1.57%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$59.96 +0.91 (+1.53%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
